5 Stocks Pushing The Health Care Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.6%) at 15,838 as of Wednesday, Jan. 29, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 929 issues advancing vs. 2,026 declining with 145 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include Bristol-Myers Squibb Company ( BMY), down 1.0%, Merck ( MRK), down 1.2%, Actavis ( ACT), down 0.9%, Covidien ( COV), down 0.9% and AstraZeneca ( AZN), down 0.7%. Top gainers within the sector include Illumina ( ILMN), up 2.8%, Regeneron Pharmaceuticals ( REGN), up 1.9%, Teva Pharmaceutical Industries ( TEVA), up 2.0%, WellPoint ( WLP), up 2.0% and Vertex Pharmaceuticals ( VRTX), up 1.4%.

TheStreet would like to highlight 5 stocks pushing the sector lower today:

5. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Care sector lower today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is down $0.59 (-1.6%) to $35.89 on average volume. Thus far, 75,713 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 147,100 shares. The stock has ranged in price between $35.76-$36.08 after having opened the day at $36.01 as compared to the previous trading day's close of $36.48.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $21.7 billion and is part of the health services industry. The company has a P/E ratio of 18.7, above the S&P 500 P/E ratio of 17.7. Shares are up 2.5% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, increase in stock price during the past year, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Novo Nordisk A/S ( NVO) is down $0.42 (-1.1%) to $37.34 on light volume. Thus far, 255,964 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $37.21-$37.54 after having opened the day at $37.50 as compared to the previous trading day's close of $37.76.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $87.1 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 2.2% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Shire ( SHPG) is down $1.62 (-1.1%) to $149.40 on light volume. Thus far, 156,461 shares of Shire exchanged hands as compared to its average daily volume of 434,800 shares. The stock has ranged in price between $147.76-$149.83 after having opened the day at $148.23 as compared to the previous trading day's close of $151.02.

Shire plc, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $27.5 billion and is part of the drugs industry. The company has a P/E ratio of 39.8, above the S&P 500 P/E ratio of 17.7. Shares are up 6.9% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Shire Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Sanofi ( SNY) is down $0.70 (-1.4%) to $48.70 on light volume. Thus far, 416,080 shares of Sanofi exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $48.26-$48.85 after having opened the day at $48.39 as compared to the previous trading day's close of $49.40.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $131.3 billion and is part of the drugs industry. The company has a P/E ratio of 26.5, above the S&P 500 P/E ratio of 17.7. Shares are down 7.9% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, GlaxoSmithKline ( GSK) is down $1.11 (-2.1%) to $52.15 on average volume. Thus far, 1.1 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $52.02-$52.35 after having opened the day at $52.15 as compared to the previous trading day's close of $53.26.

GlaxoSmithKline plc manufactures and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $128.9 billion and is part of the drugs industry. The company has a P/E ratio of 16.0, below the S&P 500 P/E ratio of 17.7. Shares are down 0.2% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst that rates GlaxoSmithKline a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices